TANDEM DIABETES CARE INC

Listed Company

TNDMCIK 0001438133NasdaqLarge AcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.01B

Net Income

$-204.71M

Total Assets

$881.11M

Equity

$155.17M

Shares Out

68.53M

Op. Cash Flow

$-9.72M

TNDM$17.07+11.17% · past yearDBEQ Basic

Daily closing prices

Business

Tandem Diabetes Care designs, develops, and commercializes advanced insulin delivery and diabetes-management solutions for people living with type 1 and type 2 insulin-dependent diabetes. The company manufactures durable insulin pumps (t:slim X2 and Tandem Mobi) featuring hybrid closed-loop automated insulin-delivery algorithms, along with single-use supplies, mobile applications, and data-management platforms. Tandem operates globally across more than 25 countries through direct sales teams in the United States, Canada, and select international markets, supplemented by independent distributors in other regions.

Summary from 10-K filed 2026-02-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Sales	1,015	940	748	801	703
Cost of sales	469	451	380	388	327
Gross profit	546	490	368	413	376
Selling, general and administrative	445	390	353	336	262
Research and development	193	199	170	139	92
Acquired in-process research and development expenses	75	0	79	31	0
Litigation and settlement expense	20	0	0	—	—
Total operating expenses	733	589	601	506	354
Operating loss	−187	−99	−233	−93	23
Interest income and other income, net	9	18	23	—	—
Interest expense	−8	−7	−10	−6	—
Loss from equity method investments	−14	−2	0	0	—
Loss on extinguishment of debt	0	−1	0	0	—
Total other income (expense), net	−13	7	13	−4,000	−7
Loss before income taxes	−200	−92	−220	−93	16
Income tax expense	4	4	2	2	335,000
Net loss	−205	−96	−223	−95	16
Unrealized gain (loss) on short-term investments	517,000	−311,000	4	—	—
Unrealized loss on cash flow hedges	−312,000	0	0	—	—
Foreign currency translation gains (losses)	7	−3	−420,000	1	−143,000
Comprehensive loss	−197	−99	−219	−96	15
Net loss per share - basic (in dollars per share)	−3.04	−1.47	−3.43	−1.47	0.25
Net loss per share - diluted (in dollars per share)	−3.04	−1.47	−3.43	−1.47	0.24
Weighted average shares used to compute basic net loss per share (in shares)	67	65	65	64	63
Weighted average shares used to compute diluted net loss per share (in shares)	67	65	65	64	64

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	91	69	59	173	71
Short-term investments	202	369	409	444	553
Accounts receivable, net	165	115	106	115	111
Inventories	129	150	158	111	69
Prepaid and other current assets	31	22	17	7	8
Total current assets	618	724	748	850	812
Property and equipment, net	84	78	77	69	50
Operating lease right-of-use assets	96	85	88	111	28
Equity method investments	60	75	0	—	—
Other long-term assets	23	5	40	24	16
Total assets	881	968	953	1,053	905
Accounts payable	47	45	50	56	28
Accrued expenses	21	18	13	10	9
Employee-related liabilities	70	64	43	39	52
Current portion of convertible senior notes, net	0	41	0	—	—
Operating lease liabilities	19	18	17	13	9
Deferred revenue	10	12	44	19	10
Other current liabilities	75	49	28	29	23
Total current liabilities	243	247	195	165	132
Convertible senior notes, net - long-term	310	308	285	283	281
Operating lease liabilities - long-term	115	106	114	124	24
Deferred revenue - long-term	8	10	13	17	17
Other long-term liabilities	50	32	32	24	18
Total liabilities	726	705	639	613	472
Commitments and contingencies (Note 14)	0	0	0	0	0
Common stock, $0.001 par value; 200,000 shares authorized, 68,291 and 66,264 shares issued and outstanding as of December 31, 2025 and 2024, respectively	68,000	66,000	66,000	65,000	64,000
Additional paid-in capital	1,402	1,313	1,264	1,171	1,068
Accumulated other comprehensive income (loss)	6	−2	1	−2	−616,000
Accumulated deficit	−1,253	−1,048	−952	−729	−635
Total stockholders equity	155	263	314	440	433
Total liabilities and stockholders equity	881	968	953	1,053	905

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−205	−96	−223	−95	16
Depreciation and amortization expense	18	17	16	14	14
Amortization of debt issuance costs	2	2	2	2	2
Provision for expected credit losses	9	10	6	5	2
Operating lease and other impairment charges	7	2	14	8	0
Amortization of discount or (accretion of premium) on short-term investments	−4	−2	4	4	365,000
Stock-based compensation expense	92	101	88	85	61
Other	4	−1	515,000	988,000	2
Accounts receivable, net	−57	−21	4	−8	−31
Inventories	25	6	−46	−42	−5
Prepaid and other current assets	−9	−6	−9	−58,000	−2
Other long-term assets	−7	893,000	−3	−1	1
Accounts payable	2	−2	−5	24	10
Accrued expenses	−664,000	6	3	−461,000	5
Employee-related liabilities	6	21	5	−13	17
Deferred revenue	−5	−35	22	8	11
Operating leases and other current liabilities	19	18	4	25	6
Other long-term liabilities	3	998,000	8	2	1
Net cash provided by (used in) operating activities	−10	24	−32	50	111
Purchases of short-term investments	−86	−264	−511	−468	−733
Proceeds from maturities and redemptions of short-term investments	257	306	546	569	570
Purchases of property and equipment	−20	−19	−27	−34	−14
Acquisition of in-process research and development	−79	0	−69	−26	0
Purchases of equity investments, strategic investments, and intangible assets	0	−46	−25	−9	−9
Net cash provided by (used in) investing activities	73	−23	−86	33	−187
Proceeds from issuance of convertible senior notes due 2029, net of $9,400 debt issuance costs	0	307	0	0	0
Repurchase of $246,740 principal amount of convertible senior notes due 2025	0	−246	0	0	—
Principal payments on convertible senior notes due 2025	−41	0	—	—	—
Payment for capped call transactions related to convertible senior notes due 2029	0	−16	0	0	0
Repurchase and retirement of common stock	0	−30	0	0	—
Cash used to settle withholding taxes on vested restricted stock, net of proceeds from issuance of common stock under Company stock plans	−3	−7	4	—	—
Other financing activities	0	183,000	−71,000	−592,000	0
Net cash provided by (used in) financing activities	−43	8	4	17	52
Effect of foreign exchange rate changes on cash	2	1	−212,000	827,000	153,000
Net increase (decrease) in cash and cash equivalents	21	10	−114	101	−23
Interest paid	5	3	8	4	4
Income taxes paid	5	3	2	411,000	260,000
Operating lease right-of-use assets obtained in exchange for operating lease obligations	26	4	0	114	15
Purchases of property and equipment included in accounts payable and accrued expenses	4	511,000	3	4	1
Intangible costs in other long-term liabilities	13	0	0	515,000	1

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is TANDEM DIABETES CARE INC's CIK number?

TANDEM DIABETES CARE INC's SEC CIK number is 0001438133 (1438133). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find TANDEM DIABETES CARE INC's SEC filings?

All of TANDEM DIABETES CARE INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did TANDEM DIABETES CARE INC last report earnings?

TANDEM DIABETES CARE INC (TNDM) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001438133-26-000048). This is TANDEM DIABETES CARE INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is TANDEM DIABETES CARE INC's most recent earnings 8-K?

TANDEM DIABETES CARE INC's latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001438133-26-000048. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View TANDEM DIABETES CARE INC's latest earnings 8-K →
Look up any company's CIK number →